Retatrutide targets GIP, GLP-1, and glucagon receptors and is currently under clinical development for obesity and type 2 diabetes
Rapid fat loss changes the neurochemical environment in ways that can temporarily worsen or alter mood
A physician-supervised plan should consider protein intake, resistance training, body composition, nutrition adequacy, dose tolerance, and symptoms such as fatigue or weakness
For managing peaks and valleys, whether for diabetes or weight, you want dosing calibrated to how you feel, not just lab values
55 RossiD.CapelloD.GloghiniA.FranceschettiS.PaulliM.BhatiaK.et al (2004)
Presentation 1: Supplementary Figures 3SB , S4 , S5D , S6A ), but metabolites differ in their changes in response to stimuli of varying amplitudes ( Presentation 1: Supplementary Figures S6 , S7 )